FTC would study pharmacy middlemen under new Senate bill
Placed on the calendarS. 527Latest action
Sponsor: Chuck Grassley · Senator · IA
AIDecoded by AI · checked against the recordRead the official text
Official title: Prescription Pricing for the People Act of 2025
119th Congress
Topics: Jobs & the economy
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
S. 527 orders the FTC to study PBMs and sole-source drug makers and report findings to Congress, without creating new rules.
35-second read · 4 questions answered below
What does this do?
The bill directs the FTC to study pharmacy benefit managers (PBMs) and other drug supply chain middlemen, with a preliminary report due in 180 days and a full report within one year. It also requires a separate FTC report on complaints against "sole-source" drug manufacturers. The bill creates no new pricing rules and does not directly regulate PBMs or drug makers.
Who does it affect?
The FTC takes on new reporting duties. PBMs, drug manufacturers, pharmacies, insurers, and consumers could be affected later if Congress acts on the findings.
Why does it matter?
The reports could inform future legislation on drug pricing transparency and competition, but the bill itself changes no current practices or prices.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedFeb 11, 2025
- Senate committee
- Senate voteYou are here · Apr 10, 2025
- House
- The president's desk
Right now: it was placed on the , and the official record shows no floor action on it since. If the House changes it, it goes back to the Senate before reaching the president.
Latest action: — Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.